Can early rectal cancer be treated without removing the rectum?

NCT ID NCT02945566

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This trial investigates whether less invasive treatments can save the rectum in people with early-stage rectal cancer. Participants receive either standard surgery (removing part of the rectum) or one of two organ-sparing approaches: short-course radiotherapy or chemoradiation (chemotherapy plus radiation), followed by close monitoring or a small local surgery. The goal is to see if these gentler options can control the cancer while avoiding a permanent stoma and reducing side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

capecitabine (chemotherapy) and radiotherapy

What this could lead to

If successful, this could offer a way to treat early rectal cancer without removing the rectum, avoiding a permanent or temporary stoma and improving quality of life.

What could go wrong

This is an early-to-mid-stage trial, so the organ-sparing approach may not control the cancer as well as standard surgery, and some patients may still need a stoma or further treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA OF THE RECTUM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rectal neoplasm rectum adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Odense University Hospital

    Odense, Denmark

  • Radboud University medical center

    Nijmegen, Netherlands

  • Region Stockholm, Onkologkliniken Södersjukhuset AB

    Stockholm, Sweden

  • University Hospital UZ Leuven

    Leuven, Belgium

  • University of Birmingham

    Birmingham, B15 2TT, United Kingdom